Search
Stories, the companies and people Loro tracks, and the primary records behind them — filings, donations, contracts and disclosures.
Company or person8
BIOTECHNOLOGY VALUE FUND L P
Company
Firsthand Technology Value Fund, Inc.
Company
Vir Biotechnology, Inc.
Company
PDS Biotechnology Corp
Company
PUMA BIOTECHNOLOGY, INC.
Company
MAIA Biotechnology, Inc.
Company
Sana Biotechnology, Inc.
Company
Nautilus Biotechnology, Inc.
Company
Primary record17
BIOTECHNOLOGY VALUE FUND L P filed SCHEDULE 13G
on Form 8-K filed with the Securities and Exchange Commission on October 15, 2026. As of the close of business on October 21, 2026, (i) BVF beneficially owned approximately 3.3% of the outstanding Shares, (ii) BVF2 benef
BIOTECHNOLOGY VALUE FUND L P filed SCHEDULE 13D/A
on August 10, 2026, and (ii) certain or all of the 3,643,838 Shares underlying the Pre-Funded Warrants held by the Reporting Persons other than Dr. Hrustanovic that are currently exercisable, as applicable, and (b) with
Foghorn Therapeutics Inc. filed SCHEDULE 13G/A
on August 6, 2026. As of the close of business on the date hereof, (i) BVF beneficially owned approximately 7.6% of the outstanding Shares, (ii) BVF2 beneficially owned approximately 5.4% of the outstanding Shares, (iii)
Stoke Therapeutics, Inc. filed SCHEDULE 13G
on August 3, 2026. As of the close of business on September 30, 2026, (i) BVF beneficially owned approximately 2.9% of the outstanding Shares, (ii) BVF2 beneficially owned approximately 2.2% of the outstanding Shares, (i
BIOTECHNOLOGY VALUE FUND L P filed SCHEDULE 13G
on August 4, 2026, and (ii) 9,079,000 Shares issued in the Issuer's offering as set forth in Issuer's Prospectus Supplement filed with the Securities and Exchange Commission on September 15, 2026. As of the close of busi
BIOTECHNOLOGY VALUE FUND L P filed 4
SEC form 4 filed by BIOTECHNOLOGY VALUE FUND L P (CIK 918923) on 2026-09-18.
Alector, Inc. filed SCHEDULE 13G
on August 6, 2026. As of the close of business on September 18, 2026, (i) BVF beneficially owned approximately 4.4% of the outstanding Shares, (ii) BVF2 beneficially owned approximately 3.3% of the outstanding Shares, (i
Avalo Therapeutics, Inc. filed SCHEDULE 13G/A
on May 13, 2026 and (ii) 726,000 Shares issuable upon the conversion of the Series C Preferred Stock owned by the Reporting Persons, as applicable. As of the close of business on June 30, 2026, (i) BVF beneficially owned
BIOTECHNOLOGY VALUE FUND L P filed SCHEDULE 13G/A
on May 14, 2026, and (ii) 1,406,826 Shares underlying certain Pre-Funded Warrants held by the Reporting Persons, as applicable. As of the close of business on June 30, 2026, (i) BVF beneficially owned approximately 5.4%
BIOTECHNOLOGY VALUE FUND L P filed SCHEDULE 13G/A
on May 8, 2026. As of the close of business on June 30, 2026, (i) BVF beneficially owned approximately 3.7% of the outstanding Shares, (ii) BVF2 beneficially owned approximately 2.8% of the outstanding Shares, (iii) Trad
BIOTECHNOLOGY VALUE FUND L P filed SCHEDULE 13G/A
on May 5, 2026. As of the close of business on June 30, 2026, (i) BVF beneficially owned approximately 4.1% of the outstanding Shares, (ii) BVF2 beneficially owned approximately 3.2% of the outstanding Shares, (iii) Trad
BIOTECHNOLOGY VALUE FUND L P filed SCHEDULE 13G/A
on May 7, 2026, (ii) 2,777,800 Shares issued to the Reporting Persons on June 26, 2026 upon the conversion of certain Series A Preferred Stock and (iii) 740,440 Shares underlying certain Series A Preferred Stock held by
BIOTECHNOLOGY VALUE FUND L P filed SCHEDULE 13G/A
on August 5, 2026 and (ii) 18,645 Shares issuable upon the exercise of certain Pre-Funded Warrants held by the Reporting Persons, as applicable. As of the close of business on June 30, 2026, (i) BVF beneficially owned ap
BIOTECHNOLOGY VALUE FUND L P filed SCHEDULE 13G/A
on May 6, 2026, (ii) 2,314,783 Shares issued to the Reporting Persons and Partners Managed Account on June 26, 2026 upon the exercise of certain Pre-Funded Warrants previously held by the Reporting Persons and Partners M
BIOTECHNOLOGY VALUE FUND L P filed SCHEDULE 13G/A
on May 7, 2026. As of the close of business on June 30, 2026, (i) BVF beneficially owned approximately 2.5% of the outstanding Shares, (ii) BVF2 beneficially owned approximately 1.9% of the outstanding Shares, (iii) Trad
BIOTECHNOLOGY VALUE FUND L P filed SCHEDULE 13G/A
on Form 8-K filed with the Securities and Exchange Commission on August 6, 2024 (the "August 2024 8-K")), would beneficially own in excess of 9.99% of the number of Shares outstanding immediately after giving effect to s
BIOTECHNOLOGY VALUE FUND L P filed SCHEDULE 13G
on August 6, 2026. As of the close of business on August 12, 2026, (i) BVF beneficially owned approximately 2.9% of the outstanding Shares, (ii) BVF2 beneficially owned approximately 2.1% of the outstanding Shares, (iii)